Companies › Curis
1 active drug program in 6 registered trials: 5 Phase 1, 1 Phase 2; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Emavusertib (CA-4948) | – | Phase 2 | Chronic Lymphocytic Leukemia; Relapsed Hematologic Malignancy; Metastatic Colorectal Adenocarcinoma; Metastatic Urothelial Carcinoma … | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06696768 | Emavusertib (CA-4948) | Phase 1 | Metastatic Colorectal Adenocarcinoma | Oncology | Dec 2026 |
| NCT06439836 | Emavusertib (CA-4948) | Phase 1 | Metastatic Urothelial Carcinoma | Oncology | Jun 2027 |
| NCT03328078 | Emavusertib (CA-4948) | Phase 1 | Relapsed Hematologic Malignancy | Oncology | Jul 2027 |
| NCT07271667 | Emavusertib (CA-4948) | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Nov 2027 |
| NCT05187182 | Emavusertib (CA-4948) | Phase 1 | Gastric Cancer | Oncology | Jul 2028 |
| NCT07107750 | Emavusertib (CA-4948) | Phase 1 | Metastatic Biliary Tract Cancer | Oncology | Jun 2030 |
Cash and short-term investments of $5m on 2026-06-30; operating cash outflow about $38m a year; runway about 2 months at that burn, to Aug 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Dogwood Therapeutics Atossa Therapeutics Processa Pharmaceuticals Moleculin Biotech Aura Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.